List of Excipients in Branded Drug ZONEGRAN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Advanz Pharma (US) Corp	ZONEGRAN	zonisamide	59212-681	CELLULOSE, MICROCRYSTALLINE
Advanz Pharma (US) Corp	ZONEGRAN	zonisamide	59212-681	GELATIN
Advanz Pharma (US) Corp	ZONEGRAN	zonisamide	59212-681	HYDROGENATED SOYBEAN OIL
Advanz Pharma (US) Corp	ZONEGRAN	zonisamide	59212-681	SODIUM LAURYL SULFATE
Advanz Pharma (US) Corp	ZONEGRAN	zonisamide	59212-681	TITANIUM DIOXIDE

ZONEGRAN Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

Zonegran, the branded formulation of zonisamide, is an immediate-release hard-gelatin capsule used primarily as adjunctive therapy for partial seizures. Its excipient platform is conventional, low-cost, and readily reproducible. The commercial opportunity is therefore not based on proprietary excipient chemistry. It is based on differentiated delivery, patient adherence, pediatric administration, supply reliability, and market access.

The strongest opportunities are lactose-free or otherwise tolerability-focused capsules, pediatric liquid or sprinkle formulations, orally disintegrating products, and cost-efficient generic manufacturing. Conventional zonisamide capsules face limited patent barriers because the core product has long been off patent and generic competition is established in the United States.

What excipients are used in Zonegran capsules?

Zonegran capsules use a conventional solid oral formulation with standard pharmaceutical excipients for fill uniformity, capsule integrity, lubrication, and product identification.

Public product information identifies the principal excipient categories as follows:

Component	Formulation role	Commercial relevance
Lactose or lactose-based diluent	Bulking agent and powder carrier	Potential issue for lactose-intolerant patients and lactose-free product developers
Pregelatinized starch or cellulose-based filler	Dilution, compressibility, and powder flow	Supports low-cost generic manufacture
Sodium lauryl sulfate	Wetting agent and dissolution aid	May affect excipient-sensitivity positioning
Magnesium stearate or hydrogenated vegetable oil	Lubrication during capsule manufacture	Standard manufacturing aid
Gelatin	Hard-capsule shell	Creates vegetarian, halal, and bovine/porcine-source substitution opportunities
Titanium dioxide and colorants	Opacity and strength identification	Relevant to clean-label and colorant-free positioning
Printing ink	Capsule identification	Supports product differentiation and counterfeit control

The precise inactive-ingredient profile can vary by jurisdiction, strength, and manufacturer. The U.S. prescribing information and product listings should control any formulation comparison. [1][2]

Zonegran is not a modified-release, osmotic, enteric-coated, lipid-based, or nanoparticle product. Its formulation design is intended to deliver zonisamide through a conventional immediate-release capsule. The label permits administration with or without food, which reduces the need for food-effect management in routine use. [1]

What is the formulation strategy for branded Zonegran?

The branded strategy is functional rather than excipient-proprietary. The capsule platform supports:

• Low manufacturing complexity.
• Standard hard-capsule filling equipment.
• Long-term room-temperature distribution.
• Multiple strengths, including 25 mg, 50 mg, and 100 mg capsules.
• Simple substitution among strengths for titration.
• Established pharmacy and wholesaler handling.

The principal formulation constraint is that zonisamide is administered chronically, often to patients who may experience swallowing difficulty, pediatric dosing challenges, cognitive impairment, or polypharmacy. A conventional capsule is commercially adequate for adults but does not fully address these use cases.

The excipient composition also creates several product-positioning questions. Lactose can limit use in patients seeking lactose-free products. Gelatin can restrict vegetarian, vegan, religious, or animal-origin-sensitive purchasing preferences. Colorants and titanium dioxide may matter in markets where customers or procurement systems prefer simpler excipient profiles.

These factors do not establish a clinical superiority claim. They create formulation and procurement differentiation.

What commercial opportunities exist for zonisamide excipient reformulation?

Lactose-free zonisamide capsules

A lactose-free capsule is the most straightforward incremental opportunity. The developer could substitute microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another suitable filler, subject to compatibility, dissolution, content uniformity, and regulatory requirements.

The commercial case is strongest where:

• Hospitals maintain lactose-free formularies.
• Pediatric or neurology clinics receive excipient-related complaints.
• Pharmacies use excipient information in product selection.
• The product is marketed outside the United States, where inactive-ingredient disclosure and patient preferences differ.

A lactose-free formulation would probably have limited ability to command a large premium because generic zonisamide is widely available. Its value would depend on dependable supply, payer placement, and pharmacy substitution controls.

Gelatin-free or vegetarian capsules

Replacing animal-derived gelatin with hypromellose or pullulan could address dietary and religious requirements. This approach is commercially relevant in the Middle East, Southeast Asia, India, and selected European markets.

The technical issues include:

• Shell moisture differences.
• Oxygen and water-vapor transmission.
• Fill-shell interaction.
• Dissolution performance.
• Mechanical behavior during high-speed filling.
• Stability under hot and humid conditions.

A hypromellose shell would not create a new active-ingredient patent position. It could support a formulation patent only if the developer claims a specific shell composition, moisture range, manufacturing process, or stability result with defensible novelty.

Pediatric oral liquid

A ready-to-use oral suspension or solution could expand access for children and patients unable to swallow capsules. The excipient strategy would need to address zonisamide’s aqueous solubility, chemical stability, taste, microbial control, and dose-measurement accuracy.

A liquid product would likely require:

• A suspending or solubilizing system.
• Taste masking.
• Preservative control or a preservative-free packaging system.
• An oral syringe with dose markings.
• Stability data after opening.
• Compatibility with bottles, closures, and dosing devices.

A compounded zonisamide suspension may already be used in clinical practice, but a commercially manufactured product would need a defined composition and validated shelf life. The opportunity is stronger in pediatrics than in the broad adult market because the dosing and swallowing problem is more acute.

Sprinkle or capsule-opening product

A capsule designed to be opened and sprinkled on soft food could improve use in pediatric and dysphagia populations without requiring a liquid product. The formulation must demonstrate dose uniformity after opening, acceptable taste, limited powder loss, and adequate stability.

This route may be less expensive to commercialize than a liquid because it avoids microbial preservation and large-volume packaging. It also preserves the basic solid-dose manufacturing platform.

Orally disintegrating tablet

An orally disintegrating tablet could target patients who have difficulty swallowing but do not require liquid dosing. Excipients could include mannitol, crospovidone, croscarmellose sodium, colloidal silicon dioxide, and taste-masking agents.

The main barrier is taste. Zonisamide products intended for oral disintegration would need effective bitterness control without delaying dissolution or increasing product mass. A product that merely changes the dosage form without improving administration may have weak commercial value against low-cost capsules.

Modified-release zonisamide

A modified-release product could reduce peak-related adverse effects or simplify dosing. The commercial and clinical burden is materially higher than for a lactose-free capsule or pediatric liquid.

A modified-release product would require evidence on:

• Release-rate control.
• Dose proportionality.
• Food effects.
• Dose dumping.
• Switching from immediate-release zonisamide.
• Seizure control across the dosing interval.
• Pharmacokinetic comparability.

The opportunity exists, but the clinical development requirement makes it less attractive than a differentiated immediate-release product.

What is the FDA regulatory status of Zonegran and generic zonisamide?

Zonegran was approved by the FDA as an oral capsule for adjunctive treatment of partial seizures. Generic zonisamide capsules are approved and marketed in the United States. The product is not a biologic, so biosimilar regulation does not apply. The relevant competitive pathway is the abbreviated new drug application, or ANDA, rather than a biosimilar application. [1][3]

A new excipient formulation could follow different regulatory routes:

Product concept	Likely U.S. pathway	Key evidence
Same strength and immediate-release capsule	ANDA if therapeutically equivalent to reference product	Bioequivalence, CMC, inactive-ingredient compliance
New liquid or sprinkle product	505(b)(2) or another applicable pathway	Pharmacokinetics, CMC, stability, administration data
Orally disintegrating tablet	505(b)(2) or ANDA depending on equivalence	Disintegration, dissolution, bioequivalence, usability
Modified-release product	505(b)(2) or full application	Comparative pharmacokinetics and clinical justification
Pediatric dosage form with new administration method	Often 505(b)(2)	Dosing, safety, palatability, stability, device validation

An excipient substitution in an ANDA must satisfy FDA requirements on inactive ingredients, route of administration, dosage form, and quantity. A product that introduces a new excipient, changes the dosage form, or makes a clinically meaningful delivery claim may require a 505(b)(2) application.

What is the Orange Book status of Zonegran?

Zonegran’s core exclusivity period has expired, and generic zonisamide capsules are available. The branded product does not have a meaningful current market position based on a blocking composition-of-matter patent.

The core commercial facts are:

Issue	Assessment
Active ingredient	Zonisamide
Reference product	Zonegran capsules
Dosage form	Immediate-release hard capsule
U.S. generic availability	Yes
NCE exclusivity	Expired
Biosimilar exposure	Not applicable
Paragraph IV relevance	Historically relevant to generic entry; limited strategic significance after broad generic entry
Current patent barrier	No evident broad blocking barrier for standard zonisamide capsules
Reformulation patent potential	Possible, but dependent on genuine formulation novelty

Orange Book listings and patent statuses change over time. Product-specific patent claims should be checked against the current FDA Orange Book and applicable patent records before a launch or licensing decision. [3]

When did Zonegran lose exclusivity?

Zonegran lost practical U.S. market exclusivity when generic zonisamide capsules entered the market. The relevant protection was tied to the original drug approval and earlier patent rights, not to a continuing formulation monopoly.

The timing has several commercial implications:

1. Standard capsules compete primarily on price, supply, wholesaler access, and formulary status.
2. A new product must provide a measurable administration or procurement benefit.
3. Patent claims directed only to routine excipient substitution may face validity and obviousness challenges.
4. A formulation with pediatric, modified-release, or device-specific functionality has a stronger basis for differentiated protection than a simple filler replacement.

What formulation patents could protect a new zonisamide product?

A new zonisamide product could seek protection in several technical areas.

Composition claims

Claims could cover a defined excipient combination, concentration range, particle-size distribution, pH range, or dissolution profile. These claims are vulnerable if the composition is an obvious selection from standard excipients.

Manufacturing-process claims

Potential claims could address:

• Low-shear blending.
• Granulation conditions.
• Lubrication time.
• Moisture-controlled capsule filling.
• Improved content uniformity.
• Reduced degradation during manufacture.

Process claims may be commercially useful if the process is difficult to replicate and produces a measurable product advantage.

Delivery-system claims

A liquid, sprinkle formulation, orally disintegrating tablet, or dosing-device combination could support claims covering the dosage form and administration method.

Method-of-use claims

A reformulated product could potentially support use claims involving a defined patient population, titration schedule, administration method, or treatment setting. Method-of-use patents must provide a credible clinical distinction and face enforcement limits where generic labels omit the patented use.

Geographic coverage

U.S. protection would be most relevant to a U.S. launch. European, Japanese, Chinese, Indian, and other national rights would need separate filings and prosecution. A global strategy should prioritize markets with:

• Significant epilepsy prevalence.
• Pediatric neurology demand.
• High generic substitution.
• Excipient-related procurement requirements.
• Weak or fragmented local supply.

How strong is the patent estate for a new Zonegran formulation?

The patent strength of a conventional capsule reformulation would generally be low to moderate. A basic lactose-free or gelatin-free substitution may be commercially useful but technically predictable.

A stronger estate would combine:

• A defined formulation with unexpected stability or dissolution results.
• A delivery device or administration method.
• A pediatric or dysphagia-focused use claim.
• Manufacturing know-how that is difficult to reverse engineer.
• Multiple patent families covering composition, process, dosage form, and use.

Trade secrets may be more valuable than patents for manufacturing controls, taste masking, suspension processing, and stability optimization. They can protect know-how without requiring disclosure, although they do not prevent independent development.

Which companies are challenging or competing with Zonegran?

The principal competition is generic zonisamide manufacturers rather than a named branded challenger. U.S. generic competition has included large and mid-sized ANDA manufacturers, with availability varying by strength, wholesaler, and time period.

Competitive pressure is greatest for:

• 25 mg and 100 mg capsules.
• High-volume pharmacy channels.
• State Medicaid and managed-care formularies.
• Institutional tenders.
• Markets with multiple approved suppliers.

Potential competitors for differentiated products include generic manufacturers with 505(b)(2) capability, specialty neurology companies, pediatric drug developers, and contract development and manufacturing organizations that can commercialize an oral liquid or multiparticulate formulation.

What generic entry risks exist for a new excipient product?

A new formulation faces four principal risks:

1. A generic manufacturer may copy the same dosage-form concept after the product demonstrates commercial demand.
2. FDA may determine that the formulation does not justify a 505(b)(2) pathway or additional exclusivity.
3. Payers may treat the product as therapeutically interchangeable with low-cost capsules.
4. Physicians may not switch stable patients unless the product solves a clear administration problem.

The strongest launch strategy is to secure a focused target population, obtain favorable formulary treatment, use packaging and dosing devices to improve adherence, and pursue patent claims tied to measurable technical performance.

What licensing opportunities exist for zonisamide excipients and delivery systems?

Zonegran itself is unlikely to offer a major licensing opportunity through its legacy excipient composition. The more attractive licensing targets are delivery platforms that can be applied to zonisamide and other antiseizure medicines.

Potential deal structures include:

• Licensing a pediatric oral-liquid platform to a specialty neurology company.
• Partnering with a capsule-shell supplier for vegetarian or region-specific capsules.
• Out-licensing a taste-masked suspension technology.
• Combining zonisamide with a proprietary oral syringe, bottle, or adherence system.
• Licensing a multiparticulate or sprinkle technology across several central nervous system drugs.

A platform deal is more valuable than a single-product transaction when the same excipient and delivery technology can support multiple active ingredients. Zonisamide could function as an initial product in a broader pediatric neurology portfolio.

What revenue exposure does Zonegran have?

Public company reporting generally does not provide a standalone, consistently reported Zonegran revenue line. The brand’s revenue exposure is therefore difficult to isolate from public financial statements. The commercial market is structurally constrained by long-established generic zonisamide competition.

Revenue potential is higher for a differentiated product than for another standard capsule. The most credible value pools are:

• Pediatric prescribing.
• Hospital and specialty-pharmacy channels.
• Patients unable to swallow capsules.
• Markets with vegetarian or halal pharmaceutical requirements.
• Supply-constrained regions.
• Products with a reimbursed administration benefit.

A simple excipient change is unlikely to generate material branded revenue without a clear channel or patient-access advantage.

Key Takeaways

• Zonegran is a conventional immediate-release zonisamide capsule with no meaningful excipient-based moat.
• Generic zonisamide competition limits the value of an undifferentiated capsule.
• Lactose-free, gelatin-free, sprinkle, liquid, and orally disintegrating formulations offer the clearest commercial opportunities.
• Pediatric and dysphagia applications provide the strongest rationale for a differentiated dosage form.
• A new product would likely rely on ANDA, 505(b)(2), or a comparable jurisdiction-specific pathway, depending on the formulation change.
• Formulation patents should cover composition, process, delivery system, and use where supportable.
• Trade secrets may provide stronger protection than narrow excipient patents for manufacturing and taste-masking know-how.
• Biosimilar risk does not apply because zonisamide is a small-molecule drug.
• Revenue potential depends more on patient access, reimbursement, and supply reliability than on the active ingredient itself.

FAQs

Can zonisamide capsules be made without lactose?

Yes. Lactose can generally be replaced with another pharmaceutical filler, subject to compatibility, content uniformity, dissolution, stability, and regulatory requirements.

Is a liquid zonisamide product commercially attractive?

Yes, particularly for pediatric patients and patients who cannot swallow capsules. The main technical barriers are taste masking, suspension stability, microbial control, and accurate dosing.

Does a gelatin-free Zonegran alternative have patent value?

The shell substitution alone would usually have limited patent strength. Patent value could improve if the formulation demonstrates unexpected stability, dissolution, manufacturability, or patient-use benefits.

Can a zonisamide sprinkle product obtain regulatory exclusivity?

Potentially. A qualifying new dosage form or administration method may support a 505(b)(2) application and applicable regulatory exclusivity, although the scope depends on the product’s clinical and regulatory distinction.

Is there biosimilar competition to Zonegran?

No. Zonisamide is a small-molecule active ingredient. Competition proceeds through generic-drug pathways, not biosimilar pathways.

References

1. U.S. Food and Drug Administration. (2023). Zonegran (zonisamide) capsules: Prescribing information. FDA.

2. European Medicines Agency. (2023). Zonegran: Summary of product characteristics. EMA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Generic drug guidance and regulatory information. FDA.

5. Eisai Co., Ltd. (2024). Annual report and product information. Eisai.